| ［1］ |
Misir S，Yaman SO，Petrovic N，et al. circRNAs in drug resistance of breast cancer ［J］. Oncol Res，2023，30（4）：157-172.
|
| ［2］ |
Mehraj U，Dar AH，Wani NA，et al. Tumor microenvironment promotes breast cancer chemoresistance ［J］. Cancer Chemother Pharmacol，2021，87（2）：147-158.
|
| ［3］ |
Dastmalchi N，Safaralizadeh R，Baghbanzadeh A，et al. Molecular mechanisms of breast cancer chemoresistance by immune checkpoints ［J］ . Life Sci，2020，263：118604.
|
| ［4］ |
Wang Y，Zeng J，Wu W，et al. Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization ［J］. Breast Cancer Res，2019，21（1）：64.
|
| ［5］ |
Oey O，Wijaya W，Redfern A. Eribulin in breast cancer：current insights and therapeutic perspectives ［J］. World J Exp Med，2024，14（2）：92558.
|
| ［6］ |
Smith JA，Wilson L，Azarenko O，et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability ［J］. Biochemistry，2010，49（6）：1331-1337.
|
| ［7］ |
Cortes J，O'shaughnessy J，Loesch D，et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer（EMBRACE）：a phase 3 open-label randomised study ［J］. Lancet，2011，377（9769）：914-923.
|
| ［8］ |
Yuan P，Hu X，Sun T，et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer：a randomised clinical trial ［J］. Eur J Cancer，2019，112：57-65.
|
| ［9］ |
Yardley DA，Reeves J，Dees EC，et al. Ramucirumab with eribulin versus eribulin in locally recurrent or metastatic breast cancer previously treated with anthracycline and taxane therapy：a multicenter，randomized，phase Ⅱ study ［J］. Clin Breast Cancer，2016，16（6）：471-479.
|
| ［10］ |
Liu B，Liu L，Ran J，et al. A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer ［J］. ESMO Open，2023，8（3）：101563.
|
| ［11］ |
Jiang M，Shao B，Wan D，et al. Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer：a retrospective multicenter study ［J］. Ther Adv Med Oncol，2023，15：17588359231204856.
|
| ［12］ |
De Angelis C，Bruzzes D，Bernardo A，et al. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab：a multicenter，phase Ⅱ，single arm trial （GIM11-BERGI） ［J］. ESMO Open，2021，6（2）：100054.
|
| ［13］ |
Tanni KA，Truong CB，Johnson BS，et al. Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer：a systematic review and meta-analysis ［J］. Crit Rev Oncol/Hematol，2021，163：103375.
|
| ［14］ |
Li Y，Han D，Hu T，et al. Efficacy and safety of eribulin-based chemotherapy in patients with advanced breast cancer：a single-centre retrospective study ［J］. J Clin Oncol，2024，42（16 Suppl）：e13121.
|
| ［15］ |
Li A，Lv Z，Zhang Z，et al. Clinical outcomes of patients with HR-positive advanced breast cancer treated with eribulin：a retrospective multicenter study from China ［J］. J Clin Oncol，2024，42（16 Suppl）：e13010.
|
| ［16］ |
Sahin TK，Rizzo A，Guven DC，et al. Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive，HER2-negative metastatic breast cancer ［J］. Cancer Treat Rev，2025，135：102924.
|
| ［17］ |
Kalinsky K，Bianchini G，Hamilton EP，et al. Abemaciclib plus fulvestrant vs fulvestrant alone for HR+，HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy：primary outcome of the phase 3 postMONARCH trial ［J］. J Clin Oncol，2024，42（17 Suppl）：LBA1001.
|
| ［18］ |
Mayer EL，Ren Y，Wagle N，et al. Abstract GS3-06： GS3-06 palbociclib after CDK4/6i and endocrine therapy （PACE）： a randomized phase Ⅱ study of fulvestrant， palbociclib， and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer ［J］. Cancer Res， 2023， 83（5 Suppl）： GS3-6-GS3-06.
|
| ［19］ |
Llombart-cussac A，Harper-wynne C，Perello A，et al. Second-line endocrine therapy（ET）with or without palbociclib（P）maintenance in patients（pts）with hormone receptor-positive（HR［+］）/human epidermal growth factor receptor 2-negative（HER2［-］）advanced breast cancer（ABC）：PALMIRA trial ［J］. J Clin Oncol，2023，41（16 Suppl）：1001.
|
| ［20］ |
Turner NC，Oliveira M，Howell SJ，et al. Capivasertib in hormone receptor-positive advanced breast cancer ［J］. N Engl J Med，2023，388（22）：2058-2070.
|
| ［21］ |
Pontolillo L，Davis AA，Gerratana L，et al. Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer：a retrospective multi-institutional Consortium analysis ［J］. NPJ Breast Cancer，2025，11（1）：93.
|
| ［22］ |
Tian Q，Gao H，Zhou Y，et al. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer：an updated meta-analysis of randomized controlled trials ［J］. Eur Rev Med Pharmacol Sci，2021，25（23）：7252-7267.
|
| ［23］ |
Hardy-bessard AC，Brocard F，Clatot F，et al. First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer：efficacy and safety in the GINECO phase Ⅱ ESMERALDA study ［J］. Breast，2020，54：256-263.
|
| ［24］ |
Funahashi Y，Okamoto K，Adachi Y，et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models ［J］. Cancer Sci，2014，105（10）：1334-1342.
|
| ［25］ |
Li S，Zhang H，Yu H，et al. Combination of eribulin and anlotinib exerts synergistic cytotoxicity in retroperitoneal liposarcoma by inducing endoplasmic reticulum stress ［J］. Cell Death Discov，2024，10（1）：355.
|
| ［26］ |
Iizumi S，Shimoi T，Tsushita N，et al. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria：a retrospective study ［J］. BMC Cancer，2017，17（1）：819.
|
| ［27］ |
Zhao Y，Xie N，Li W，et al. Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China：a multicenter retrospective study ［J］. Ther Adv Med Oncol，2021，13：17588359211030210.
|